Azacitidine use in elderly patients (over 65) with high risk myelodysplasia/acute myeloid leukaemia.

Phase 4

• Conditions: myelodysplasia; acute myeloid leukaemia; Blood - Haematological diseases; Cancer - Leukaemia - Acute leukaemia

• Registration Number: ACTRN12613000358741
• Lead Sponsor: Illawarra Private Cancer Care Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

>65 years old
Diagnosis of high-risk myelodysplasia or acute myeloid leukaemia on bone marrow biopsy.

Exclusion Criteria

Azacitidine use contraindicated.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
% mean survival[18 months]

Secondary Outcome Measures

Name	Time	Method
Haematological improvement in at least one cytopenia[4-18 months<br>Monthly assessment of cytopenias.];Decreased transfusion requirement.[4-18 months<br>Ongoing assessment of transfusion required. For example, if the gap between transfusions moves from 2 weeks to 3 weeks, this is an improvement. Each participant has the record of the transfusion requirement updated each time they are transfused (variable time between participants)]